ATTR-CM

The oral therapy acoramidis has been approved in Brazil, to be sold as Beyonttra, for treating adults with hereditary or wild-type transthyretin amyloid cardiomyopathy…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to coramitug, an experimental treatment in late-stage clinical testing for transthyretin…

A blood test measuring levels of the protein MR-proADM may help predict heart failure events (worsening of symptoms requiring immediate medical care) and death in…

Starting Attruby (acoramidis) early and taking it continuously helps adults with transthyretin amyloid cardiomyopathy (ATTR-CM) live longer, stay out of the hospital for…

People with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) are significantly more likely to have a history of agricultural work, manual labor, and greater upper-body physical…

Amvuttra (vutrisiran) was associated with improvements in quality of life and physical function in adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). That’s according…

Alnylam Pharmaceuticals is supporting two initiatives aiming to transform transthyretin amyloid cardiomyopathy (ATTR-CM) management, with a focus on earlier diagnosis and more coordinated…

Women with transthyretin amyloid cardiomyopathy (ATTR-CM) show differences in disease features and greater physical limitations than men, but are less likely to be given…

Blood levels of the transthyretin (TTR) protein at the start of Vyndaqel (tafamidis) treatment and after one month may help identify which patients with wild-type…

The U.S. Food and Drug Administration (FDA) has lifted its hold on a large-scale clinical trial evaluating nexiguran ziclumeran, Intellia Therapeutics’ gene-editing therapy candidate,…